EUVIMEDEUVIMED entdecken
Crossref

Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia

Ryeska Fajar Respaty, Santi Purna Sari, Bambang Widyantoro

Expert Review of Pharmacoeconomics & Outcomes Research · 05.11.2026 · 1-10

DOI: 10.1080/14737167.2026.2760016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 05.11.2026. Verfasst von Ryeska Fajar Respaty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adding milrinone to dobutamine (dobutamine-milrinone escalation) in cardiogenic shock (CS) is reimbursed for a limited duration under Indonesia's national health insurance, but its cost structure is poorly characterized. This study quantified direct medical charges associated with escalation and the contribution of drug acquisition. RESEARCH DESIGN AND METHODS: Retrospective cohort of 76 adult CS survivors (20 escalation, 56 dobutamine monotherapy) at Indonesia's national cardiovascular referral center, 2020-2024. Covariate Balancing Propensity Score-based inverse probability of treatment weighting, using pre-treatment covariates, estimated adjusted cost ratios (CR) for intensive cardiovascular care unit (ICVCU) and total hospital costs from institutional billing records. RESULTS: Escalation was associated with higher ICVCU costs (CR 2.711; 95% CI 1.912-3.844; p

Schlagwörter

Stichwörter der Autor:innen

Cardiogenic shockIndonesiacost analysisdobutamineinotrope escalationmilrinonepropensity scorereimbursement policy

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
  • Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Department of Cardiology, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.

Zitieren

APA

Fajar Respaty, R., Purna Sari, S., & Widyantoro, B. (2026). Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia. Expert Review of Pharmacoeconomics & Outcomes Research, 1-10. https://doi.org/10.1080/14737167.2026.2760016

Vancouver

Fajar Respaty R, Purna Sari S, Widyantoro B. Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-10. doi:10.1080/14737167.2026.2760016

BibTeX
@article{FajarRespaty2026,
  author = {Fajar Respaty, Ryeska and Purna Sari, Santi and Widyantoro, Bambang},
  title = {Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  pages = {1--10},
  doi = {10.1080/14737167.2026.2760016}
}
Kostenlos starten →